A PYMNTS Company

Belgium Opens Competition Case Focusing on IQVIA’s Business Practices

By  |  December 9, 2025

The Belgian Competition Authority (BCA) has initiated formal proceedings to examine whether IQVIA, a global provider of data and technology services for the life sciences industry, may have violated competition rules in Belgium’s pharmaceutical data market.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to a statement, authorities began scrutinizing the company after receiving a complaint and conducting an initial review that raised significant concerns about potentially anti-competitive behavior. The investigation will focus on IQVIA’s contractual practices in the collection and analysis of pharmaceutical and healthcare data — a market described as highly concentrated in Belgium.

    Per the statement, BCA officials requested information from various organizations operating in the sector before determining that there were sufficient indications of a possible breach of laws prohibiting the abuse of a dominant market position under EU and Belgian competition rules. This decision has now triggered a formal inquiry under the Code of Economic Law.

    The healthcare and pharmaceutical sphere has been a strategic enforcement priority for the authority in recent years, given its impact on public welfare and innovation in medical products. Investigators are expected to assess whether IQVIA’s business conduct could restrict competition or limit fair access to essential data services used by drug developers and medical device manufacturers.

    Officials emphasized that the launch of the case does not imply any conclusion about IQVIA’s liability. The company will have the opportunity to participate fully as the proceedings advance, and the investigation remains at an early stage.

    Source: Belgian Competition